Literature DB >> 8187473

Prevalence and patterns of "dual diagnosis" among psychiatric inpatients.

A F Lehman1, C P Myers, E Corty, J W Thompson.   

Abstract

Studies of patients admitted to public mental hospitals have consistently found high rates of comorbid substance use disorders. We sought a better understanding of this comorbidity among psychiatric inpatients, in particular differentiating two groups of "dual diagnosis" patients, (1) those with independent mental disorders complicated by substance use disorders, and (2) those with psychoactive substance use disorder-induced organic mental disorders (PSUD-induced OMD). The diagnoses of 435 consecutively admitted inpatients from an inner-city catchment area were ascertained with the Structured Clinical Interview for DSM-III-R (1987 Inpatient Version [SCID-P]), modified to describe more accurately the relationships between psychiatric syndromes and substance use. More than half (55.9%) of these psychiatric patients had current substance use disorders. Over half (53.6%) of these "dually diagnosed" patients had no lifetime history of an independent mental disorder, but rather had psychiatric syndromes related to psychoactive substance use. The dual diagnosis subgroups differed on treatment history, principal psychiatric diagnoses, and the types of substances used. The results underscore the heterogeneity of dual diagnosis patients admitted to psychiatric hospitals and the potential importance of differentiating among these subgroups.

Entities:  

Mesh:

Year:  1994        PMID: 8187473     DOI: 10.1016/0010-440x(94)90054-l

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  14 in total

1.  Use of potentially abusive psychotropic substances in psychiatric inpatients.

Authors:  J Modestin; C Nussbaumer; K Angst; P Scheidegger; D Hell
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

2.  Clients with substance abuse and mental health concerns: a guide for conducting intake interviews.

Authors:  Christiane Brems; Mark E Johnson; Lorraine L Namyniuk
Journal:  J Behav Health Serv Res       Date:  2002-08       Impact factor: 1.505

3.  Perceived reasons for substance misuse among persons with a psychiatric disorder.

Authors:  Alexandra B Laudet; Stephen Magura; Howard S Vogel; Edward L Knight
Journal:  Am J Orthopsychiatry       Date:  2004-07

Review 4.  Organizational guidelines for dual disorders programs.

Authors:  C C Mercer; K T Mueser; R E Drake
Journal:  Psychiatr Q       Date:  1998

5.  Longitudinal Course of Clients With Co-occurring Schizophrenia-Spectrum and Substance Use Disorders in Urban Mental Health Centers: A 7-Year Prospective Study.

Authors:  Robert E Drake; Alison E Luciano; Kim T Mueser; Nancy H Covell; Susan M Essock; Haiyi Xie; Gregory J McHugo
Journal:  Schizophr Bull       Date:  2015-08-19       Impact factor: 9.306

6.  Predictors of Length of Stay in an Inpatient Psychiatric Unit of a General Hospital in Perugia, Italy.

Authors:  Luca Pauselli; Norma Verdolini; Francesco Bernardini; Michael T Compton; Roberto Quartesan
Journal:  Psychiatr Q       Date:  2017-03

7.  Impact of Family History in Persons With Dual Diagnosis.

Authors:  Camille S Wilson; Melanie E Bennett; Alan S Bellack
Journal:  J Dual Diagn       Date:  2012-11-27

8.  Demographic and clinical correlates of substance abuse comorbidity in schizophrenia.

Authors:  Tapas K Aich; Vinod K Sinha; Christoday R J Khess; Shailja Singh
Journal:  Indian J Psychiatry       Date:  2004-04       Impact factor: 1.759

9.  A comparison of schizophrenic patients with or without coexisting substance use disorder.

Authors:  Coreen Farris; Christiane Brems; Mark E Johnson; Rebecca Wells; Randall Burns; Nicholas Kletti
Journal:  Psychiatr Q       Date:  2003

10.  Prevalence of psychotic symptoms in substance users: a comparison across substances.

Authors:  Matthew J Smith; Jagadisha Thirthalli; Arbi Ben Abdallah; Robin M Murray; Linda B Cottler
Journal:  Compr Psychiatry       Date:  2008-09-23       Impact factor: 3.735

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.